Pharmasset, Inc. (NASDAQ: VRUS)

Pharmasset, Inc. (NASDAQ: VRUS), a clinical-stage pharmaceutical company, is focused on discovering, developing and commercializing innovative drugs for the treatment of viral infections. The company’s primary focus is on developing of oral therapeutics for the treatment of hepatitis B virus, hepatitis C virus and human immunodeficiency virus (HIV). Their product candidates include: Clevudine (for treating chronic HBV infection), R7128 (for treating HCV), and R7128 (for treating HIV). For further information, visit the Company’s web site at www.pharmsset.com.